(Albany, United States) As per DelveInsight’s assessment, globally, the Non-Muscle Invasive Bladder Cancer Pipeline constitutes 25+ key companies continuously working towards developing 30+ Non-Muscle Invasive Bladder Cancer Pipeline treatment therapies, analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments analysis DelveInsight.
In the Non-Muscle Invasive Bladder Cancer Pipeline Report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, Non-Muscle Invasive Bladder Cancer NDA approvals (if any), and product development activities comprising the technology, Non Muscle Invasive Bladder Cancer collaborations, licensing, mergers and acquisition, funding, designations and other product related details.
To explore more information on the latest breakthroughs in the Non-Muscle Invasive Bladder Cancer Pipeline treatment landscape of the report, click here @ Non-Muscle Invasive Bladder Cancer Pipeline Outlook
Key Takeaways from the Non-Muscle Invasive Bladder Cancer Pipeline Report
DelveInsight’s Non-Muscle Invasive Bladder Cancer Pipeline analysis depicts a robust space with 25+ active players working to develop 30+ pipeline treatment therapies.
The leading companies working in the Non-Muscle Invasive Bladder Cancer Market include Bristol-Myers Squibb, Pfizer, Asieris Pharmaceuticals, Incyte Corporation, Janssen Pharmaceuticals, Theralase Technologies, Aura Biosciences, Protara Therapeutics, Vaxiion Therapeutics, Tollys, and others.
Promising Non-Muscle Invasive Bladder Cancer Pipeline CG0070, Pembrolizumab Injection, TLD1433 infusion and photodynamic therapy (PDT) treatment, Durvalumab, cis-UCA solution, ADSTILADRIN, TARA-002, N803 plus Bacillus Calmette-Guerin (BCG), VB4-845 Injection, PF-06801591, and others.
On August 2023, AstraZeneca announced a study of phase 3 clinical trials for Durvalumab and BCG. The purpose of this study is to assess the safety, tolerability, and efficacy profile of durvalumab + BCG (induction and maintenance) combination therapy in adult United States participants with a histologically confirmed diagnosis of high-risk non-muscle-invasive bladder cancer (NMIBC), who have received no prior systemic therapy for NMIBC, and who are BCG-naïve.
On August 2023, Ferring Pharmaceuticals announced a study of phase 3 clinical trias for ADSTILADRIN. Previous multi-dose Phase I and Phase II clinical studies have demonstrated that ADSTILADRIN is a safe and effective treatment for BCG-refractory and recurrent NMIBC. This Phase III study is designed to expand those observations using a high dose of ADSTILADRIN in patients that are “BCG Unresponsive” which refers to patients with high-grade NMIBC who are unlikely to benefit from and should not receive further intravesical BCG.
Non-Muscle Invasive Bladder Cancer Overview
Non muscle-invasive bladder cancer (NMIBC) is a heterogeneous subclassification of urothelial carcinoma with significant variation in individual risk of recurrence and progression to muscle-invasive disease. It is a cancer found in the tissue that lines the inner surface of the bladder.
For further information, refer to the detailed Non-Muscle Invasive Bladder Cancer Unmet Needs, click here for Non-Muscle Invasive Bladder Cancer Ongoing Clinical Trial Analysis
Non-Muscle Invasive Bladder Cancer Emerging Drugs Profile
APL-1202: Asieris Pharmaceuticals
Pemigatinib: Incyte Corporation
VAX 014: Vaxiion Therapeutics
Non-Muscle Invasive Bladder Cancer Pipeline Therapeutics Assessment
There are approx. 25+ key companies which are developing the therapies for Non Muscle Invasive Bladder Cancer. The companies which have their Non Muscle Invasive Bladder Cancer drug candidates in the most advanced stage, i.e. Phase III include, Asieris Pharmaceuticals.
Request a sample and discover the recent advances in Non-Muscle Invasive Bladder Cancer Ongoing Clinical Trial Analysis and Medications, Click here for more details @ Non-Muscle Invasive Bladder Cancer Segmentation
Non-Muscle Invasive Bladder Cancer Drugs and Companies
cis-UCA solution: BioCis Pharma Ltd
ADSTILADRIN: Ferring Pharmaceuticals
TARA-002: Protara Therapeutics
Non-Muscle Invasive Bladder Cancer Therapeutics Assessment
Assessment by Stage and Product Type
Assessment by Route of Administration
Assessment by Stage and Route of Administration
Assessment by Molecule Type
Assessment by Stage and Molecule Type
Some of the Companies in the Non-Muscle Invasive Bladder Cancer Therapeutics Market include-
Bristol-Myers Squibb, Pfizer, Asieris Pharmaceuticals, Incyte Corporation, Janssen Pharmaceuticals, Theralase Technologies, Aura Biosciences, Protara Therapeutics, Vaxiion Therapeutics, Tollys, and others.
Dive deep into rich insights for drugs for Non-Muscle Invasive Bladder Cancer Pipeline, click here @ Non-Muscle Invasive Bladder Cancer Unmet Needs and Analyst Views
Scope of the Non-Muscle Invasive Bladder Cancer Pipeline Report
Coverage- Global
Companies- Bristol-Myers Squibb, Pfizer, Asieris Pharmaceuticals, Incyte Corporation, Janssen Pharmaceuticals, Theralase Technologies, Aura Biosciences, Protara Therapeutics, Vaxiion Therapeutics, Tollys, and others.
Therapies- CG0070, Pembrolizumab Injection, TLD1433 infusion and photodynamic therapy (PDT) treatment, Durvalumab, cis-UCA solution, ADSTILADRIN, TARA-002, N803 plus Bacillus Calmette-Guerin (BCG), VB4-845 Injection, PF-06801591, and others.
Segmentation: Product Type, Molecule Type, Route of Administration
Got Queries? Find out the related information on Non-Muscle Invasive Bladder Cancer Merger and acquisitions, Licensing Activities
Table of Content
Introduction
Executive Summary
Non Muscle Invasive Bladder Cancer: Overview
Pipeline Therapeutics
Therapeutic Assessment
Non Muscle Invasive Bladder Cancer– DelveInsight’s Analytical Perspective
Late Stage Products (Phase III)
APL-1202: Asieris Pharmaceuticals
Drug profiles in the detailed report…..
Mid Stage Products (Phase II)
Pemigatinib: Incyte Corporation
Drug profiles in the detailed report…..
Early Stage Products (Phase I)
VAX 014: Vaxiion Therapeutics
Drug profiles in the detailed report…..
Preclinical and Discovery Stage Products
Drug Name: Company Name
Drug profiles in the detailed report…..
Inactive Products
Non Muscle Invasive Bladder Cancer Key Companies
Non Muscle Invasive Bladder Cancer Key Products
Non Muscle Invasive Bladder Cancer- Unmet Needs
Non Muscle Invasive Bladder Cancer- Market Drivers and Barriers
Non Muscle Invasive Bladder Cancer- Future Perspectives and Conclusion
Non Muscle Invasive Bladder Cancer Analyst Views
Non Muscle Invasive Bladder Cancer Key Companies
Appendix
About Us
DelveInsight is a Business Consulting and Market research company, providing expert business solutions for the healthcare domain and offering quintessential advisory services in the areas of R&D, Strategy Formulation, Operations, Competitive Intelligence, Competitive Landscaping, and Mergers and acquisitions.
Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: Send Email
Phone: 9193216187
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/consulting-services